A detailed history of Charles Schwab Investment Management Inc transactions in Annexon, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 732,216 shares of ANNX stock, worth $3.76 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
732,216
Previous 227,560 221.77%
Holding current value
$3.76 Million
Previous $1.12 Million 288.7%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.49 - $7.2 $2.27 Million - $3.63 Million
504,656 Added 221.77%
732,216 $4.33 Million
Q2 2024

Aug 12, 2024

BUY
$4.33 - $6.79 $201,383 - $315,796
46,509 Added 25.69%
227,560 $1.12 Million
Q1 2024

May 08, 2024

BUY
$4.03 - $7.81 $231,253 - $448,161
57,383 Added 46.4%
181,051 $1.3 Million
Q2 2023

Aug 09, 2023

BUY
$2.1 - $6.37 $219,105 - $664,620
104,336 Added 539.71%
123,668 $435,000
Q3 2022

Nov 14, 2022

SELL
$3.75 - $6.63 $370,653 - $655,315
-98,841 Reduced 83.64%
19,332 $120,000
Q2 2022

Aug 15, 2022

SELL
$2.11 - $4.06 $148,847 - $286,408
-70,544 Reduced 37.38%
118,173 $446,000
Q1 2022

May 13, 2022

SELL
$2.73 - $11.94 $17,021 - $74,445
-6,235 Reduced 3.2%
188,717 $516,000
Q4 2021

Feb 11, 2022

BUY
$11.49 - $22.0 $46,247 - $88,550
4,025 Added 2.11%
194,952 $2.24 Million
Q3 2021

Nov 16, 2021

BUY
$16.35 - $23.4 $818,513 - $1.17 Million
50,062 Added 35.54%
190,927 $3.55 Million
Q2 2021

Aug 16, 2021

BUY
$17.81 - $27.48 $212,758 - $328,276
11,946 Added 9.27%
140,865 $3.17 Million
Q1 2021

May 17, 2021

BUY
$22.0 - $35.01 $563,156 - $896,185
25,598 Added 24.78%
128,919 $3.59 Million
Q4 2020

Feb 16, 2021

BUY
$20.81 - $30.55 $161,027 - $236,395
7,738 Added 8.1%
103,321 $2.59 Million
Q3 2020

Nov 13, 2020

BUY
$17.5 - $30.23 $1.67 Million - $2.89 Million
95,583 New
95,583 $2.89 Million

Others Institutions Holding ANNX

About Annexon, Inc.


  • Ticker ANNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,617,700
  • Market Cap $245M
  • Description
  • Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...
More about ANNX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.